Can Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR)’s Tomorrow Be Different? The Stock Had Decline in Shorts

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Logo

The stock of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) registered a decrease of 4.55% in short interest. ARWR’s total short interest was 15.76M shares in March as published by FINRA. Its down 4.55% from 16.51 million shares, reported previously. With 2.14 million shares average volume, it will take short sellers 7 days to cover their ARWR’s short positions.

The stock decreased 0.10% or $0.02 during the last trading session, reaching $19.3. About 1.26 million shares traded. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has risen 215.92% since March 13, 2018 and is uptrending. It has outperformed by 211.55% the S&P500.

Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. The company has market cap of $1.82 billion. The Company’s pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. It currently has negative earnings. The firm also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma.

More notable recent Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) news were published by: which released: “Why Arrowhead Pharmaceuticals, Inc. Stock Slumped Today – Nasdaq” on July 30, 2018, also with their article: “Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q4 2018 Results – Earnings Call Transcript – Seeking Alpha” published on December 11, 2018, published: “Nasdaq nails 200-day average, S&P 500 extends break atop major resistance – MarketWatch” on February 13, 2019. More interesting news about Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) were released by: and their article: “Arrowhead’s HBV candidate shows positive action in early-stage study; shares up 16% premarket – Seeking Alpha” published on September 06, 2018 as well as‘s news article titled: “Analysts React To Arrowhead’s Janssen Collaboration: Downside May Be ‘Misguided’ (NASDAQ:ARWR) – Benzinga” with publication date: October 04, 2018.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Ratings Chart

(adsbygoogle = window.adsbygoogle || []).push({});

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.